Results of landmark Mindbloom study exceed those of traditional antidepressant studies

Mindbloom’s outcomes data were part of the second-largest peer-reviewed study of ketamine therapy (we also published the largest). This study showed that Mindbloom drove significant improvements in depression — results that are even stronger than those seen in studies of traditional therapies.^1,2,3,4,5

Summary at-a-glance

Over 1,200 Mindbloom clients were part of a landmark peer-reviewed study of ketamine therapy published in the Journal of Affective Disorders showing that Mindbloom drove significant improvements in anxiety and depression.

The results of the study were shown to be:

• 54% stronger than studies of talk therapy⁴
• 34% stronger than studies of SSRI antidepressants³
• 17% stronger than studies of IV ketamine⁵

Only 4 clients (0.3%) dropped out of treatment due to adverse events or intolerable side effects.

This clinical study shows that Mindbloom can be a safe and effective option for managing mental health.

‍

‍

“This landmark study showed outcomes for at-home ketamine therapy that far exceeded those of traditional depression treatments,” says Mindbloom Medical Director Dr. Leonardo Vando. “We believe that the support provided by our clinicians and guides and the comfort of our at-home treatments contribute to the therapy’s effectiveness.”

Here are the study’s key results…

At-home ketamine therapy with Mindbloom produced stronger outcomes than those shown in other studies of antidepressants and psychotherapy

Participants’ symptoms were measured before and after treatment, and after 4 sessions:

• 89% reported an improvement in symptoms 
• 63% reported a 50% or greater reduction in symptoms
• 33% achieved remission (or virtually no symptoms)

When compared to studies of traditional therapies^2,3,4 and IV ketamine,⁵ at-home ketamine therapy produced a greater improvement in symptoms.

‍

• 34% higher than those of SSRI antidepressants^,3
• 54% higher than those of psychotherapy⁴
• 17% higher than those seen in IV ketamine —despite Mindbloom’s less invasive and lower-cost at-home treatments⁵
• Mindbloom’s study reported these outcomes after 4 weeks, while SSRI and psychotherapy studies required 2+ months to achieve reported results^3,4

Study indicates safety of at-home treatment

The study showed that at-home ketamine therapy was not only effective but safe, with minimal side effects or adverse events reported by participants.

• Only 4 patients (0.3%) dropped out of treatment due to adverse events or intolerable side effects.
• Fewer than 1% of the study’s participants’ experienced worsening of symptoms over the course of the study.
• Fewer than 5% of participants reported any side effects.

At-home ketamine therapy also provided remission from suicidal thoughts

Mindbloom’s at-home ketamine therapy brings hope to those who have lived with thoughts of self-harm and suicide.

• 62% of patients who reported suicidal ideation at baseline no longer reported any suicidal ideation after 4 sessions.
• Suicide ideation (SI) was defined as a score >0 on PHQ item 9. Of the 295 participants who reported SI baseline, 67 reported SI after 4 sessions and 119 did not complete the assessment.

“The results of this study make it clear that ketamine therapy is the future of mental healthcare,” says Mindbloom Founder and CEO Dylan Beynon. “This groundbreaking study is an opportunity to dispel common misconceptions about ketamine therapy, and to help us bring its healing power to more people than ever before.” 

The study was written by physicians and researchers from the psychiatry departments of Cleveland Clinic, UCSF, NYU, and Houston Methodist. Its Senior Author is Principal Investigator for the MAPS Phase 3 MDMA-assisted therapy for PTSD clinical trial. 

Read the full study here, “At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial”

Why this study is important

The United States continues to experience a growing mental health care crisis:

• Anxiety and depression are a leading cause of disability in the United States, and almost half of adults will have a mental illness in their lifetime.⁶
• Over 60% of adults with a mental illness don't receive care, with cost being by far the most cited reason.⁷
• Further, ​​1/3 of people with major depression are treatment resistant.⁸

This growing epidemic is currently outpacing the number of clinicians available to provide care.⁹ By raising awareness and increasing access to at-home therapies like Mindbloom, we can reach more people in need and give people more tools to manage their mental health.

Want to learn more about at-home ketamine therapy?

• To learn more about Mindbloom’s at-home ketamine therapy, visit our homepage.

• If you’re ready to explore at-home ketamine therapy, take our brief candidate assessment.

• To better understand how ketamine interacts with your brain, read our guide on the neuroscience of ketamine.

• For safety information about ketamine, click here.

• Questions about Mindbloom? Reach out to our client relations team at support@mindbloom.com.

‍

References:

1. Hull, T. D., Malgaroli, M., Gazzaley, A., Akiki, T. J., Madan, A., Vando, L., Arden, K., Swain, J., Klotz, M., & Paleos, C. (2022). At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. Journal of Affective Disorders, 314, 59–67. https://doi.org/10.1016/j.jad.2022.07.004 

2. Taliaz, D., Spinrad, A., Barzilay, R. et al. Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Transl Psychiatry 11, 381 (2021). https://doi.org/10.1038/s41398-021-01488-3

3. Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., Shores-Wilson, K., Biggs, M. M., Balasubramani, G. K., & Fava, M. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in star*d: Implications for clinical practice. American Journal of Psychiatry, 163(1), 28–40. https://doi.org/10.1176/appi.ajp.163.1.28 

4. Cuijpers, P., Karyotaki, E., Ciharova, M., Miguel, C., Noma, H., & Furukawa, T. A. (2021). The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatrica Scandinavica, 144(3), 288–299. https://doi.org/10.1111/acps.13335 

5. McInnes, L. A., Qian, J. J., Gargeya, R. S., DeBattista, C., & Heifets, B. D. (2022). A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. Journal of Affective Disorders, 301, 486–495. https://doi.org/10.1016/j.jad.2021.12.097 

6. Substance Abuse and Mental Health Services Administration. (2020). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/

7. The State Of Mental Health In America. Mental Health America. Retrieved May 31, 2023, from https://mhanational.org/issues/state-mental-health-america#:~:text=Over%20half%20(54.7%25)%20of,illness%20did%20not%20receive%20care

8. Brown, J. (2020, February 3). 4 things we now know about treatment-resistant depression. Content Lab U.S. Retrieved July 14, 2022, from https://www.jnj.com/health-and-wellness/4-facts-about-treatment-resistant-depression 

‍9. Hoge, M. A., Stuart, G. W., Morris, J. A., Huey, L. Y., Flaherty, M. T., & Paris Jr., M. (2019). Behavioral Health Workforce Development in the United States. Substance Abuse and Addiction, 433–455. https://doi.org/10.4018/978-1-5225-7666-2.ch023